AbTherx and Spice Biotechnologies Announce Multi-Program Antibody Discovery Collaboration
Immuno-oncology pioneer partners with AbTherx to build the next generation of immunotherapy drugs
MOUNTAIN VIEW, CA / ACCESS Newswire / May 12, 2025 / AbTherx, Inc., a biotechnology company with innovative transgenic technologies that enable and accelerate antibody discovery, today announced a multi-program antibody discovery partnership with Spice Biotechnologies. The partnership will leverage AbTherx's suite of innovative Atlas™ Mouse technologies to deliver antibodies against targets selected by Spice Bio.
AbTherx's antibody discovery platform is built on two decades of experience and utilizes evolutionary intelligence to identify diverse and developable human antibody sequences. This collaboration leverages AbTherx's novel, patent-pending Atlas Full Human Diversity Mouse, an updated industry standard with a strong IP position that generates fully human antibodies with the affinity and diversity required for efficient, successful drug development. It also utilizes the Binary Fixed Light Chain Transgenic Mouse which enables native-like IgG bispecific antibodies that improve manufacturability and developability. Through these innovative technologies and a deeply collaborative partnering model, AbTherx uniquely enables startups to efficiently manage resources, timelines, and technical risk.
Spice Bio was founded by Alan J. Korman, a globally recognized leader in immunology and cancer research. With over 30 years of experience in drug development, Dr. Korman has shaped groundbreaking advancements in the field, most recently serving as an executive at Vir Biotechnology and Bristol Myers Squibb. Dr Korman led the discovery of a revolutionary approach to cancer immune therapy and immune checkpoint blockade, which has driven the development and approval of several groundbreaking oncology drugs. Working with AbTherx cofounders at Medarex and BMS, Dr. Korman found incredible success discovering and developing the world's first immune checkpoint inhibitors, YERVOY® (ipilimumab) and OPDIVO® (nivolumab).
'Over the last 20 years, the Spice Bio team has had an incredible track record of creating successful life-saving drugs in partnership with some of our AbTherx cofounders. Because of this long, productive history, we are particularly excited to partner with Dr. Korman again in his new venture to create the next generation of immunotherapy drugs,' said Justin Mika, Chief Executive Officer of AbTherx. 'AbTherx is uniquely positioned to lead the next wave of antibody therapeutics with continuous innovation in antibody discovery technology, deep experience in antibody discovery, and startup-friendly partnering models.'
From top 10 pharmaceutical companies to virtual startups, leading organizations in antibody therapeutics have rapidly adopted the AbTherx platform, resulting in over 50 initiated programs across over a dozen partners in the past nine months. Under the terms of the agreement, Spice Bio has the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbTherx will receive research payments and is eligible to receive downstream clinical and commercial milestone payments, as well as royalties on net sales of products.
About AbTherx
AbTherx is advancing medicine with revolutionary technologies that accelerate and enable therapeutic antibody discovery. Through an exclusive license from Gilead Sciences, AbTherx has released Atlas™ Mice, a suite of novel transgenic technologies designed for unmatched performance and Freedom to Operate. For over 20 years, a core group of AbTherx's scientists have worked together to push the boundaries of antibody discovery technologies, resulting in more than 1,000 successful discovery campaigns and the development of 13 marketed therapeutics. AbTherx's industry-leading team creates transformative solutions to overcome the most demanding challenges in delivering innovative medicines. Committed to making its technologies accessible to all, AbTherx offers flexible partnering models that meet the needs of drug developers of all sizes. For more information, please visit www.abtherx.com.
Media Contact
Stacey Borders
[email protected]
SOURCE: AbTherx, Inc.
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
11 minutes ago
- The Hill
States sue 23andMe over genetic data sales
More than two dozen states, along with the District of Columbia, are suing biotechnology company 23andMe over plans to auction off personal genetic information without their customers' knowledge or consent. The lawsuit, which was filed Monday by twenty-seven states in the U.S. Bankruptcy Court in the Eastern District of Missouri, says that the California-based firm, which filed for bankruptcy in March, cannot sell off customers' sensitive data without obtaining consent from each of the individuals. 'New Yorkers and many others around the country trusted 23andMe with their private information and they have a right to know what will be done with their information. My office is joining 27 other attorneys general to protect people's most private information and to make sure 23andMe abides by the law,' New York Attorney General Letitia James (D) said in a news release on Tuesday. The human genetics firm, founded in 2006, filed for Chapter 11 bankruptcy in March in U.S. federal court in Missouri. The company gained popularity for its at-home DNA tests. Customers had to send saliva samples by mail and then they would get genetic reports. 23andMe has collected biological samples and genetic information for more than 15 million consumers. Regeneron Pharmaceuticals, another biotechnology company, said last month that it would purchase for $256 million. When it filed for bankruptcy, 23andMe said the personal information of customers could be accessed, transferred or sold as part of a transaction, but the potential buyers will have to comply with its privacy policies. Regeneron Pharmaceuticals said it would follow the outlined policies and the laws on-hand. Customers can erase their data from the 23andMe site. House lawmakers launched an investigation a month after the biotech company filed for bankruptcy, expressing concerns over the individuals' data and added that some users were unable to delete their information off the website.
Wall Street Journal
38 minutes ago
- Wall Street Journal
Bloomberg Endorses Cuomo for New York City Mayor
Former New York City Mayor Michael Bloomberg has endorsed Andrew Cuomo's mayoral campaign, giving the former governor of New York a boost from a prominent moderate political voice heading into the final weeks before the Democratic primary. Bloomberg said Tuesday he has had his differences with Cuomo over the years, but when they disagreed, Cuomo showed strengths as a leader and a manager.
Skift
41 minutes ago
- Skift
Corporate Travel's New Boss: The Finance Department
Finance teams have quietly become power players in corporate travel. The shift began years ago but has sped up post-pandemic. The challenge now? Ensuring that the traveler experience and domain expertise aren't lost in the numbers. The balance of power in corporate travel decision-making has been shifting for years — but in 2025, the trend has become unmistakable. Travel programs, once firmly in the hands of procurement or travel departments, are now increasingly led or co-owned by finance teams. According to travel managers interviewed by Skift, finance is no longer just reviewing expense reports — it's shaping policy, selecting platforms, and tightening oversight. 'We provide input, but HR, finance, and procurement all weigh in,' said Sushant Saini, a corporate travel and expense manager. 'Post-Covid, finance has taken a much more active role. They're focused on every detail.' One travel manager, who requested anonymity, said the shift began before the pandemic but accelerated significantly during it. Do Finance Departments See the Whole Picture? Companies are embracing a more cross-functional approach to travel management, but the finance-first mindset is clearly gaining ground. In many organizations, finance departments now hold primary or shared ownership over travel policy, signaling a deeper strategic integration. While the increased structure and data rigor are welcomed, the transition hasn't been frictionless. 'Travel management goes beyond numbers and data,' Saini said. 'While finance brings structure, travel requires soft skills and negotiation to deliver real value. Being proactive and using smarter tools helps build trust across teams.' The anonymous travel manager echoed the sentiment. 'Finance often overlooks the human side of travel programs. Sometimes you need to be more than logical to get better deals or compliance,' she said. Still, both agreed that finance's growing role — when paired with the operational expertise of travel managers — has the potential to create smarter, more agile programs. Travel Managers Adapt to Finance's Growing Influence Travel Management Companies (TMCs) are rolling out new tools to support finance's deeper role in travel oversight. 'Eighty-one percent of CFOs now see themselves as primary growth drivers,' said Chris Juneau, SVP of Product Marketing at SAP Concur, citing findings from the company's CFO Insights report. Concur's new tools, including Concur Verify and the AI copilot Joule, aim to improve accuracy, streamline expense audits, and deliver real-time analytics. At Navan, Chief Financial Officer Amy Butte emphasized the need for visibility and control. 'In the past, finance only saw travel spend after the fact,' Butte said. 'Now, with our Advanced Analytics, they can spot trends, policy violations, and savings opportunities in real time.' Emburse: General Motors Finance Had Improved Control Emburse CEO Marne Martin said its Travel and Expense Analytics platform was built to solve finance leaders' pain points, including fragmented systems, unclear data, and poor visibility. Martin cited General Mills as a case study. With over 34,000 employees, General Mills adopted Emburse Go to centralize travel and expense management via a mobile app. This helped improve compliance and gave finance and employees better control and visibility. AI-driven features, Martin said, are increasingly helping finance teams enforce policies dynamically, adjusting per diems by city, identifying fraud, and analyzing spending behavior with little manual intervention.
